Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Rosing

Showing results (141-150 of 175) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1993
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patientsM T Huizing, A C Keung, H Rosing, et al.
British Journal of Cancer|December 18, 2001
A phase I and pharmacokinetic study of intraperitoneal topotecanL S Hofstra, A M Bos, E G de Vries, et al.
Journal of Mass Spectrometry : JMS|June 10, 2003
Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometryE Stokvis, L Nan-Offeringa, H Rosing, et al.
Breast Cancer Research and Treatment|July 15, 2018
Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifenM van Nuland, R A Vreman, R M T Ten Ham, et al.
Anti-Cancer Drugs|May 4, 2001
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxelJ M Meerum Terwogt, W W ten Bokkel Huinink, J H Schellens, et al.
Investigational New Drugs|February 1, 2017
Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase IIC M Nijenhuis, L Lucas, H Rosing, et al.
British Journal of Cancer|November 27, 2001
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patientsM M Malingré, J H Schellens, O Van Tellingen, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2018
Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of <sup>14</sup>C-plitidepsinL van Andel, H Rosing, M M Tibben, et al.
Anti-Cancer Drugs|October 18, 2001
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in manR W Sparidans, H Rosing, M J Hillebrand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancerC M F Kruijtzer, J H M Schellens, J Mezger, et al.
Pageof 18

Showing results (141-150 of 175) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1993
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patientsM T Huizing, A C Keung, H Rosing, et al.
British Journal of Cancer|December 18, 2001
A phase I and pharmacokinetic study of intraperitoneal topotecanL S Hofstra, A M Bos, E G de Vries, et al.
Journal of Mass Spectrometry : JMS|June 10, 2003
Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometryE Stokvis, L Nan-Offeringa, H Rosing, et al.
Breast Cancer Research and Treatment|July 15, 2018
Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifenM van Nuland, R A Vreman, R M T Ten Ham, et al.
Anti-Cancer Drugs|May 4, 2001
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxelJ M Meerum Terwogt, W W ten Bokkel Huinink, J H Schellens, et al.
Investigational New Drugs|February 1, 2017
Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase IIC M Nijenhuis, L Lucas, H Rosing, et al.
British Journal of Cancer|November 27, 2001
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patientsM M Malingré, J H Schellens, O Van Tellingen, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2018
Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of <sup>14</sup>C-plitidepsinL van Andel, H Rosing, M M Tibben, et al.
Anti-Cancer Drugs|October 18, 2001
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in manR W Sparidans, H Rosing, M J Hillebrand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancerC M F Kruijtzer, J H M Schellens, J Mezger, et al.
Pageof 18